Results 41 to 50 of about 158,858 (186)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients [PDF]

Journal of Medical Biochemistry, 2020
Background: This study aimed at investigating the feasibility of testing for soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in serum samples of glioma patients and to evaluate the diagnostic and prognostic value of ...
Liu Shujun, Zhu Yadi, Zhang Chenxi, Liu Jiajia, Lv Hong, Zhang Guojun, Kang Xixiong   +6 more
doaj   +2 more sources

Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy

Cancer Management and Research, 2021
Rong Fu,1 Chuan-Qing Jing,1 Xiu-Rong Li,2 Zhao-Feng Tan,2 Hui-Jie Li2 1Clinical Department of Integrated Traditional Chinese and Western Medicine, The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, People ...
Fu R, Jing CQ, Li XR, Tan ZF, Li HJ
doaj   +1 more source

Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients

Allergology International, 2017
Background: T-cell response outcome is determined by co-stimulatory/inhibitory signals. Programmed cell death-1 ligand-1 (PD-L1) is a member of these co-signaling molecules with known soluble form in human serum. Soluble PD-L1 (sPD-L1) is also recognized
Rasoul Nasiri Kalmarzi, Nima Fattahi, Zeinab Kaviani, Pedram Ataee, Majid Mansouri, Ghobad Moradi, Alireza Yousefzade, Javid Morad Abbassi   +7 more
doaj   +2 more sources

Assessment of soluble PD-L1 in septic shock in relation to immunosuppressive phenotypes [PDF]

Annals of Intensive Care
Background: Septic shock triggers a complex immune response characterized by the coexistence of hyperinflammation and immunosuppression, the latter being a major driver of ICU-acquired infections and increased mortality.
Camille Bonnet, Anne-Perrine Foray, Eléonore Micoud, Thomas Lafon, Morgane Gossez, Anne-Claire Lukaszewicz, Fabienne Venet, Guillaume Monneret   +7 more
doaj   +2 more sources

Белки sPD-1/sPD-L1 при немелкоклеточном раке легкого и плоскоклеточном раке пищевода

, 2022
Background. Implementation of immunotherapy in clinical oncological practice has significantly improved the results of cancer treatment. It resulted in the need for seeking new markers to assess the effectiveness of therapy and the disease prognosis.Aim.
P. V. Tsarapaev, Е. М. Чевкина, П. В. Царапаев, Э. А. Сулейманов, O. V. Kovaleva, A. N. Gratchev, П. А. Подлесная, E. A. Suleymanov, И. С. Стилиди, I. S. Stilidi, А. Н. Грачев, N. E. Kushlinskii, О. В. Ковалева, P. A. Podlesnaya, E. M. Tchevkina, Н. Е. Кушлинский   +15 more
core   +1 more source

Exploratory characterization of dynamic soluble programmed death-ligand 1 trajectories and their association with mortality in critical coronavirus disease 2019 [PDF]

Journal of Intensive Care
Background Persistent immune checkpoint activation is a recognized feature of critical coronavirus disease 2019 (COVID-19). However, the temporal behavior and clinical utility of soluble programmed death-ligand 1 (sPD-L1) remain unclear.
Shungo Takeuchi, Eiji Kawamoto, Takashi Matsusaki, Daisuke Ono, Yosuke Sakakura, Arong Gaowa, Eun Jeong Park, Motomu Shimaoka, Ryuji Kaku   +8 more
doaj   +2 more sources

Analysis of the cellular and soluble immune checkpoint components PD-L1 and sPD-L1 in renal cell carcinoma

, 2021
Das Nierenzellkarzinom (RCC) zählt in Deutschland zu den zehn am häufigsten vorkommenden Tumor-entitäten. Während bei lokal begrenzten Tumoren eine operative Tumorresektion mit kurativer Zielsetzung möglich ist, führt es im metastasierten ...
Wegner, Moritz Justus Philipp
core   +1 more source

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma

OncoImmunology, 2020
Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents.
Christopher Montemagno, Anais Hagege, Delphine Borchiellini, Brice Thamphya, Olivia Rastoin, Damien Ambrosetti, Juan Iovanna, Nathalie Rioux-Leclercq, Camillio Porta, Sylvie Negrier, Jean-Marc Ferrero, Emmanuel Chamorey, Gilles Pagès, Maeva Dufies   +13 more
doaj   +1 more source

Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode

Bioelectrochemistry, 2021
This work describes the modification of a gold electrode with the BMS-8 compound that interacts with the Programmed Death-Ligand 1 (PD-L1), an immune checkpoint protein. The results show that we can confirm the presence of the sPD-L1 in the concentration range of 10-18 to 10-8 M using electrochemical impedance spectroscopy (EIS) with a limit of ...
Paweł Niedziałkowski, Magdalena Bojko, Jacek Ryl, Anna Wcisło, Marta Spodzieja, Katarzyna Magiera-Mularz, Katarzyna Guzik, Grzegorz Dubin, Tad A. Holak, Tadeusz Ossowski, Sylwia Rodziewicz-Motowidło   +10 more
openaire   +3 more sources

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations

Frontiers in Oncology, 2020
Programmed cell death ligand 1 (PD-L1) expressed on tumor tissues is a vital molecule for immune suppression and its impact on the response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been reported.
Yijun Jia, Xuefei Li, Chao Zhao, Shengxiang Ren, Chunxia Su, Guanghui Gao, Wei Li, Fei Zhou, Jiayu Li, Caicun Zhou   +9 more
doaj   +1 more source